Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Receivables - Net (2019 - 2024)

Historic Receivables - Net for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to $54.8 million.

  • Pharming's Receivables - Net rose 1877.25% to $54.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $54.8 million, marking a year-over-year increase of 1877.25%. This contributed to the annual value of $54.8 million for FY2024, which is 1877.25% up from last year.
  • Pharming's Receivables - Net amounted to $54.8 million in Q4 2024, which was up 1877.25% from $46.2 million recorded in Q4 2023.
  • Over the past 5 years, Pharming's Receivables - Net peaked at $54.8 million during Q4 2024, and registered a low of $27.6 million during Q4 2022.
  • Moreover, its 5-year median value for Receivables - Net was $34.9 million (2020), whereas its average is $38.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 1398.48% in 2021, then soared by 6712.41% in 2023.
  • Pharming's Receivables - Net (Quarter) stood at $34.9 million in 2020, then decreased by 13.98% to $30.0 million in 2021, then dropped by 7.88% to $27.6 million in 2022, then skyrocketed by 67.12% to $46.2 million in 2023, then increased by 18.77% to $54.8 million in 2024.
  • Its Receivables - Net was $54.8 million in Q4 2024, compared to $46.2 million in Q4 2023 and $27.6 million in Q4 2022.